AI Article Synopsis
- The study aimed to evaluate how effective first-line immune checkpoint inhibitor (ICI) combinations are for treating metastatic renal cell carcinoma (mRCC) patients based on age.
- After reviewing five randomized controlled trials, the results showed that ICI combinations significantly improved overall survival (OS) compared to sunitinib alone for both younger (<65 years) and older (≥65 years) patients, but the benefit was notably greater for younger patients.
- The findings suggest that ICI combinations did not enhance OS for patients aged 75 and older, indicating that age can influence treatment decisions and patient outcomes.
Article Abstract
To compare the efficacy of first-line immune checkpoint inhibitor (ICI)-based combinations in metastatic renal cell carcinoma (mRCC) patients stratified by chronological age. According to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, hazard ratios for overall survival (OS) from randomized controlled trials were synthesized. Five RCTs were eligible for meta-analyses. ICI-based combinations significantly improved OS compared with sunitinib alone, both in younger (<65 years) and older (≥65 years) patients, whereas the OS benefit was significantly better in younger patients (p = 0.007). ICI-based combinations did not improve OS in patients aged ≥75 years. Treatment rankings showed age-related differential recommendations regarding improved OS. OS benefit from first-line ICI-based combinations was significantly greater in younger patients. Age-related differences could help enrich shared decision-making.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/imt-2023-0039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!